Hot Investor Mandate 3: Institutional Fund Manager Invests in Early and Growth Stage Healthcare Innovations for China Market

29 Dec

A professional investment institution based in Shanghai invests in early and growth stage companies in the field of biomedicine through its fund management company. The firm currently manages its $100 million fund that is set to close in 2017Q1. Typical equity investments range from US$0.5 to 4 million in Angel to Series B rounds. The firm is currently seeking opportunities from China, the US and Canada.

The firm’s key areas of focus include medicine, medical devices, diagnostics, biotechnology and healthcare services. The firm is seeking products that have large market potential in China and have achieved prototype and clinical proof-of-concept. The firm is agnostic when it comes to indication areas.

The firm is looking for competent management teams with validated assets. The firm can assist with finding registration and distribution partners in China and may request regional rights on a case-by-case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: